Encouraging News for Hepatitis C Vaccine

[Guest guest]

Encouraging News for Hepatitis C Vaccine

Preliminary phase I data for a therapeutic T-cell Hepatitis C vaccine posts hopeful results.

First Vaccine for Viral Hepatitis C Could Become a Reality

Wednesday, April 06, 2011

Early data from phase I trials of an HCV vaccine presented at the International Liver Congress show encouraging results, with high immunogenicity and good safety profile.

BERLIN, GERMANY -- In the first study¹, a therapeutic T-cell vaccine, based on novel adenoviral vectors was used on a small population of treatment naive patients with chronic genotype 1 HCV infection. Intra-muscular vaccination was administered 2 or 14 weeks into a 48-week course of treatment with Peg-IFNa2a/ribavirin. 50% of vaccinated patients had CD4+ and CD8+ HCV specific T-cell responses as detected by ELISpot at 2-8 weeks post boost, showing a strong immunogenicity for the vaccine. Local and systemic adverse events to vaccination were mild, with no evidence of liver immunopathology (measured by liver transaminase levels).

Continue reading this entire article:http://www.mdnews.com/news/2011_04/first-vaccine-for-viral-hepatitis-c-could-become-a-reality

http://www.hepatitis-central.com/mt/archives/2011/04/encouraging_new.html